N
INBX

Natixis’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Natixis’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-11,000
Closed -$418K – 1282
2023
Q4 		$418K Buy
+11,000
New +$236K ﹤0.01% 645
2023
Q3 		– Sell
-45,000
Closed -$1.17M – 1177
2023
Q2 		$1.17M Buy
+45,000
New +$1.05M 0.01% 517

Other funds holding INBX

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Natixis's INBX Position: Q1 2024 in Review

Natixis sold out of Inhibrx, Inc. Common Stock (INBX) in Q1 2024, closing a stake of 11,000 shares — an estimated $418K sold.

Natixis first reported a position in INBX in Q2 2023 and held it in 2 quarters. The position peaked at $1.17M in Q2 2023. 126 funds tracked by Wall St. Rank hold INBX as of Q1 2024.

  • Natixis reported no remaining Inhibrx, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Natixis sold 11,000 Inhibrx, Inc. Common Stock shares in Q1 2024, an estimated $418K.
  • Natixis first reported a position in Inhibrx, Inc. Common Stock in Q2 2023 and held it in 2 quarters.
  • Natixis's Inhibrx, Inc. Common Stock position peaked at $1.17M in Q2 2023.
  • 126 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q1 2024.

Based on Natixis's 13F filing for Q1 2024, filed 13 May 2024.